151751-Najiba-Chargi

291 Systemic therapy: skeletal muscle mass changes and chemoradiotherapy 28. Cole CL, Kleckner IR, Jatoi A, Schwarz E, Dunne RF. The Role of Systemic Inflamma - tion in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clin Reports . 2018;3(2). doi:10.17987/jcsm-cr.v3i2.65 29. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sar- copenic obesity in patients with solid tu- mours of the respiratory and gastrointesti- nal tracts: a population-based study. Lancet Oncol . 2008;9(7):629-635. doi:10.1016/ S1470-2045(08)70153-0 30. Daly LE, Ní Bhuachalla ÉB, Power DG, Cushen SJ, James K, Ryan AM. Loss of skel - etal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcope- nia Muscle . 2018;9(2):315-325. doi:10.1002/ jcsm.12267 31. Huang X, Ma J, Li L, Zhu X dong. Severe muscle loss during radical chemoradiother- apy for non-metastatic nasopharyngeal carcinoma predicts poor survival. Cancer Med . 2019;8(15):6604-6613. doi:10.1002/ cam4.2538 32. Faithfull S, Turner L, Poole K, et al. Preha - bilitation for adults diagnosed with cancer: A systematic review of long-term physical function, nutrition and patient-report- ed outcomes. Eur J Cancer Care (Engl) . 2019;28(4). doi:10.1111/ecc.13023 33. Palma S, Hasenoehrl T, Jordakieva G, Ra - mazanova D, Crevenna R. High-intensity interval training in the prehabilitation of cancer patients—a systematic review and meta-analysis. Support Care Cancer . 2020. doi:10.1007/s00520-020-05834-x 15